Kashi Clinical Laboratories
10101 SW Barbur Blvd, Suite 200
Portland, OR 97219

1 877 879-1815
1000 characters left

Contact Information

Other Information

Practice Information

Thank you for your interest in Kashi Health's genetic testing services.

Our genetic tests require guidance from a licensed healthcare provider. You may find a qualified provider from our list of approved professionals in the link below, or you may email your provider directly requesting that they contact us to request a genetic test. We wish you the best in your pursuit of healthy living.


Bone Health Panel

The Kashi Bone Health Panel gives insight into how each patient absorbs the nutrients important for proper bone health, allowing for patients and healthcare providers to make informed dietary and supplement choices.

Strong bones are critical to good health. While healthy bones are influenced by environmental elements such as nutrition, genetics also play a major role. Osteoporosis, characterized by low bone mass, is a major problem in older adults. Today, about 30 to 50 percent of American women and 15 to 30 percent of American men experience an osteoporosis-related fracture in their lifetimes. Studies have demonstrated that bone mineral density in older adults is influenced by genes underlying bone accrual and bone loss; in fact, up to 85 percent of the variation in peak bone mineral density can be explained by genetic factors. However, only recently have these specific genes, and their variants, been identified.

Why Test?

Knowing which genes will ultimately have the greatest impact on bone health allows physicians to recommend genetic testing for early identification of individuals prone to low bone mineral density. Identifying patients with genetic variants in the genes or gene regions of GC, NADSYN1/DHCR7, CYP2R1, WNT16, and ESR1 (genes known to be associated with increased risk for fracture or lower bone mineral density), may allow for the implementation of strategies to delay the onset of osteoporosis, and reduce the severity of bone loss and potential fractures later in life.

Ideal Candidates are Patients with the Following Symptoms or Conditions:

  • Diagnosed with osteoporosis or osteopenia
  • Conditions that prevent proper vitamin D absorption
  • Individuals with compromised mobility
  • People in low sun exposure areas
  • Menopausal changes
  • History of a minimal-trauma fracture
  • Low blood calcium (hypocalcemia)
  • Low blood phosphate (hypophosphatemia)

Genetic Markers Included in the Bone Health Panel

Vitamin D Tests three genes that function in the Vitamin D metabolism pathway involved in transportation of vitamin D to target organs, conversion of the inactive form of vitamin D to the active form, and bioavailability of the vitamin D precursor
WNT16 Essential to proper protein signaling involved in the regulation of bone formation
Estrogen Receptor 1 Crucial to the process of bone resorption

  • How are the Test Categories Selected

    There are numerous genes that are found all along our chromosomes, and in many cases there are no physiological consequences for possessing one allele versus another. Consequently, before inclusion in the Bone Health panel each gene has been carefully researched by Kashi's PhD level scientists to assure that only the most informative genetic markers that have a well-established impact on health would be included in the test. Every gene that is included in the genetic panel has been carefully selected based upon the following criteria:

    1.  Several clinical trials published in peer-reviewed scientific journals have reported a connection between the gene and optimal bone health.

    2. The gene must have a well established connection with bone health as measured by bone mass density, risk of fractures, osteoporosis, or be integral to the genetic pathways that govern bone development and remodeling.

    3. All variants are chosen based upon the scientific evidence of their association either with critical parameters necessary to maintaining optimal bone health, or evidence of their association with the risk of developing potentially serious bone health diseases or consequences.

Tying it all Together

The genetic markers included in the Kashi Bone Health Panel have been rigorously analyzed by our experienced researchers. It is Kashi Health's mission to provide healthcare providers with a deeper understanding of the genetic basis of their patients' bone and joint health, to provide more timely and effective care.

Get Started Today

Make Kashi Health's Genetic Testing Part of Your Patient's Treatment Plan.

Questions? Please contact our customer service team at 877-879-1815 or 503-206-4989 or by email at This email address is being protected from spambots. You need JavaScript enabled to view it. . We are available Monday through Friday, from 8:00 AM - 5:00 PM, Pacific Time.

  1. Estrada K et al. Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet. 2012; 44(5):491–501.
  2. Koller DL et al. Meta-analysis of genome-wide studies identifies WNT16 and ESR1 snps associated with bone mineral density in premenopausal women.  J Bone Miner Res. 2013; 28(3):547–558.
  3. Haussler CA et al. Molecular Mechanisms of Vitamin D Action. Calcified Tissue International 2013; 92:77-98
  4. Kim JH et al. Wnt signaling in bone formation and its therapeutic potential for bone diseases. Ther Adv Musculoskel Dis. 2014; 5(1):13–31.
  5. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville (MD): Office of the Surgeon General (US): 2004.